Analyzing Petros Pharmaceuticals (NASDAQ:PTPI) and Virpax Pharmaceuticals (NASDAQ:VRPX)

Risk & Volatility

Virpax Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Valuation & Earnings

This table compares Virpax Pharmaceuticals and Petros Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19 million	($123.25)	0.00
Petros Pharmaceuticals	$5.11 million	0.05	-$8.16 million	($39.69)	0.00

Petros Pharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Virpax Pharmaceuticals and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.